Condition: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) · Sponsor: ToLymph Inc.
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
This description comes directly from the study's public registry record.
Jennifer Lister / Clinical Research Coordinator / UHN · 1-416-340-4857 · jennifer.lister@uhn.ca
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Toronto General Hospital | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06693336